Evolus (EOLS) Competitors $9.20 -0.07 (-0.70%) Closing price 03:59 PM EasternExtended Trading$9.21 +0.01 (+0.05%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. ARWR, APLS, NAMS, TWST, DNLI, KNSA, AGIO, RXRX, CGON, and VCELShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors Arrowhead Pharmaceuticals Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Denali Therapeutics Kiniksa Pharmaceuticals International Agios Pharmaceuticals Recursion Pharmaceuticals CG Oncology Vericel Evolus (NASDAQ:EOLS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends. Does the media refer more to EOLS or ARWR? In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than Evolus. MarketBeat recorded 4 mentions for Arrowhead Pharmaceuticals and 3 mentions for Evolus. Arrowhead Pharmaceuticals' average media sentiment score of 0.85 beat Evolus' score of 0.77 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EOLS or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Evolus' net margin of -20.40%. Arrowhead Pharmaceuticals' return on equity of -45.33% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-20.40% -759.04% -20.14% Arrowhead Pharmaceuticals N/A -45.33%-12.49% Which has stronger earnings & valuation, EOLS or ARWR? Evolus has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$275.46M2.15-$50.42M-$0.89-10.34Arrowhead Pharmaceuticals$3.55M711.39-$599.49M-$1.40-13.06 Which has more volatility and risk, EOLS or ARWR? Evolus has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Do analysts recommend EOLS or ARWR? Evolus presently has a consensus target price of $23.75, suggesting a potential upside of 158.01%. Arrowhead Pharmaceuticals has a consensus target price of $43.71, suggesting a potential upside of 139.05%. Given Evolus' stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals and insiders have more ownership in EOLS or ARWR? 90.7% of Evolus shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 6.1% of Evolus shares are held by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryEvolus beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$593.50M$10.21B$5.57B$9.32BDividend YieldN/A2.09%4.23%4.03%P/E Ratio-10.3416.9728.6419.75Price / Sales2.1529.25432.34182.50Price / CashN/A22.6736.0257.96Price / Book102.283.608.235.67Net Income-$50.42M$233.40M$3.24B$257.98M7 Day Performance-4.71%-2.71%0.05%0.56%1 Month Performance-7.58%1.84%5.65%8.88%1 Year Performance-23.42%-18.71%26.57%14.24% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.876 of 5 stars$9.21-0.7%$23.75+158.0%-23.2%$593.50M$275.46M-10.34170ARWRArrowhead Pharmaceuticals3.5639 of 5 stars$16.84+0.3%$43.71+159.6%-38.9%$2.33B$3.55M-12.03400News CoverageAPLSApellis Pharmaceuticals4.2287 of 5 stars$17.42-4.6%$39.79+128.4%-51.6%$2.19B$781.37M-9.73770News CoverageAnalyst ForecastAnalyst RevisionNAMSNewAmsterdam Pharma2.7421 of 5 stars$19.46-2.0%$42.89+120.4%+7.3%$2.18B$45.56M-10.354TWSTTwist Bioscience4.1794 of 5 stars$35.59-6.8%$50.40+41.6%-35.2%$2.13B$312.97M-10.95990DNLIDenali Therapeutics4.6765 of 5 stars$14.25-3.0%$33.71+136.6%-39.3%$2.07B$330.53M-5.34430Positive NewsKNSAKiniksa Pharmaceuticals International3.3683 of 5 stars$27.95+0.3%$38.80+38.8%+30.0%$2.04B$481.17M-111.80220Upcoming EarningsAGIOAgios Pharmaceuticals4.3771 of 5 stars$35.21-2.4%$58.60+66.4%-16.5%$2.04B$36.50M3.13390News CoverageAnalyst RevisionRXRXRecursion Pharmaceuticals1.8109 of 5 stars$4.93-6.5%$7.00+42.0%-36.3%$2.00B$59.82M-2.79400High Trading VolumeCGONCG Oncology2.7542 of 5 stars$26.25-2.4%$58.67+123.5%-31.9%$2.00B$662K-17.3861News CoveragePositive NewsAnalyst ForecastVCELVericel3.6942 of 5 stars$39.41-5.6%$61.14+55.1%-25.6%$1.98B$237.22M1,314.10300News CoveragePositive News Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Twist Bioscience Competitors Denali Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors Agios Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors CG Oncology Competitors Vericel Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EOLS Stock Alerts